Pill with imprint IP 102 IP 102 is Beige, Capsule/Oblong and has been identified as Gabapentin 300 mg. It is supplied by Amneal Pharmaceuticals.
Gabapentin is used in the treatment of Back Pain; Postherpetic Neuralgia; Epilepsy; Chronic Pain; Seizures and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 300 mg is not a controlled substance under the Controlled Substances Act (CSA).
Gabapentin
- Imprint
- IP 102 IP 102
- Strength
- 300 mg
- Color
- Beige
- Size
- 19.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Gamma-aminobutyric acid analogs
- Pregnancy Category
- C – Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Amneal Pharmaceuticals
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 53746-0102 (Discontinued) | Amneal Pharmaceuticals LLC |
| 65162-0102 | Amneal Pharmaceuticals LLC |
| 42291-0301 (Discontinued) | AvKare, Inc. |
| 63739-0689 (Discontinued) | McKesson Packaging Services |
| 63739-0236 | McKesson Packaging Services |
| 54868-5166 (Discontinued) | Physicians Total Care Inc. (repackager) |
| 53002-1423 | Pharmedix (repackager) |
| 33261-0049 | Aidarex Pharmacuticals, LLC (repackager) |
The efficacy of Gabapentin in the treatment of neuropathic pain has been demonstrated in several placebo-controlled studies. In a study involving 502 patients with neuropathic pain treated with Gabapentin at a dose of 300 to 1800 mg/day, efficacy was assessed by the percentage of patients who had a 50% or more reduction in pain. Gabapentin has been shown to be effective in 69% of patients receiving 900 or 1800 mg per day, and in 57% of patients taking 300-600 mg of Gabapentin. In approximately 80% of patients responding to therapy, the effect persisted after discontinuation of the drug.
Amneal Pharmaceuticals
Amneal Pharmaceuticals is a U.S.-based pharmaceutical company known for developing, manufacturing, and distributing generic and specialty pharmaceutical products. Here is an overview of the company:
Company Overview
- Founding and History:
- Founded: In 2002 by brothers Chirag and Chintu Patel.
- Headquarters: Bridgewater, New Jersey, USA.
- Growth: The company has grown significantly since its inception, becoming one of the largest generic drug manufacturers in the United States.
- Operations and Facilities:
- Manufacturing: Amneal operates multiple manufacturing facilities in the United States, including sites in New York, New Jersey, and Kentucky, as well as internationally.
- Research and Development: The company invests heavily in R&D to develop new generic and specialty pharmaceutical products.
- Product Portfolio:
- Generics: Amneal’s portfolio includes a wide range of generic medications covering various therapeutic areas, such as oncology, central nervous system, cardiovascular, anti-infective, and anti-inflammatory drugs.
- Specialty Pharmaceuticals: The company also focuses on branded pharmaceuticals, particularly in areas like neurology, endocrinology, and infectious diseases.
- Biosimilars: Amneal is involved in developing biosimilars, which are biologic products highly similar to FDA-approved reference products.
- Acquisitions and Partnerships:
- Amneal has grown through strategic acquisitions and partnerships. Notable acquisitions include Impax Laboratories, which helped expand its specialty pharmaceutical and generic drug offerings.
- The company also collaborates with other pharmaceutical companies and research institutions to enhance its product pipeline and market presence.
- Regulatory Compliance:
- Amneal adheres to stringent regulatory standards set by the U.S. Food and Drug Administration (FDA) and other global regulatory bodies to ensure the quality, safety, and efficacy of its products.
- The company undergoes regular inspections and audits to maintain compliance with Good Manufacturing Practices (GMP).
- Market Presence:
- Amneal products are distributed globally, and the company has a significant market presence in the United States, Europe, and other international markets.
- The company supplies pharmaceuticals to wholesalers, distributors, retail chains, and healthcare providers.
- Corporate Responsibility:
- Amneal is committed to corporate social responsibility, focusing on sustainable practices, ethical business conduct, and community engagement.
- The company also engages in philanthropic efforts, including donations and support for healthcare initiatives and education.
Conclusion
Amneal Pharmaceuticals is a prominent player in the pharmaceutical industry, known for its extensive range of generic and specialty pharmaceuticals. With a strong focus on research and development, regulatory compliance, and strategic growth, Amneal continues to expand its presence in the global pharmaceutical market. The company’s commitment to quality and innovation positions it as a key provider of affordable and accessible healthcare solutions.